Episode 218 - JD Finley & Mitch Jones - Palisade Bio

<p>On this episode we&#39;re joined by Palisade Bio&#39;s CEO &amp; CMO, JD Finley &amp; Mitch Jones.</p><p>In Q2 2026, Palisade released promising ph1 data for their lead asset - PALI2108 - a PDE4 inhibitor. With recent IND clearance for their ph2 ASCENTRA-UC study, we discuss that data, and what real success looks like clinically &amp; commercially for the business &amp; asset moving forward, in an increasingly busy IBD market. </p><p>We hope you enjoy the episode.</p>